

Rivaroxaban for Children Aged Over 2 Years With Giant Coronary Artery Aneurysms After Kawasaki Disease

NCT05643651

Status	RECRUITING
Phase	Phase 4
Sponsor	Children's Hospital of Fudan University
Enrollment	100 participants

Key Eligibility Criteria

Inclusion (4)

- Giant coronary artery aneurysm(s) in any coronary artery after acute stage of Kawasaki disease. Giant coronary artery aneurysm(s) should be confirmed by two-dimensional echocardiography and meet the diagnostic criteria of Z-score ≤ 10 or coronary artery internal diameter ≥ 8 mm;
- Anticoagulant with antiplatelet drug therapy for anti-thromboprophylaxis is recommended for the next 3 months;
- Participant should be able to tolerate oral feeding, nasogastric or gastric feeding;
- Children aged ≥ 2 years

Exclusion (12)

- Active bleeding or bleeding risk contraindicating anticoagulant therapy
- With history of venous thromboembolism or risk factors related with venous thromboembolism, like congenital heart disease, carcinoma, central venous catheter or long-term immobilization.
- Thrombus within giant coronary aneurysm was confirmed by previous imaging examinations, including two-dimensional echocardiography, computed tomography angiography in coronary artery or coronary angiography
- An eGFR < 30 mL/min/1.73 m² (For children younger than 1 year, serum creatinine results above 97.5th percentile)
- Platelet count $< 100 \times 10^9$ /L
- ... and 7 more (see full listing online)

Locations (1 total)

Children's Hospital of Fudan University, Shanghai, Shanghai Municipality, China